Descartes-08 is under clinical development by Cartesian Therapeutics and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData, Phase II drugs for Systemic Lupus Erythematosus have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Descartes-08’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Descartes-08 overview
Descartes-08 is under development for the treatment of myasthenia gravis, systemic lupus erythematosus and unspecified autoimmune diseases. The therapeutic candidate consists of T cells modified by mRNA to express chimeric antigen receptors (CAR T-cells). It acts by targeting BCMA and is developed based on CAR-T cell technology. It is RNA CAR T-cell (rCAR-T) therapy.
It was under development for the treatment of multiple myeloma.
Cartesian Therapeutics overview
Cartesian Therapeutics (Cartesian), formerly Selecta Biosciences, is a clinical-stage biotechnology company. It offers a proprietary technology and manufacturing platform, RNA Armory, which is designed to develop mRNA cell therapies for the treatment of autoimmune diseases. The company’s pipeline products include Descartes-08, Descartes-15 and Descartes-33. Its lead product Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen, which treats myasthenia gravis and systemic lupus erythematosus, other autoimmune diseases; Descartes-15 for autoimmune diseases and myeloma and Descartes-33, which is in preclinical development targets autoimmune diseases. Cartesian is headquartered in Gaithersburg, Maryland, the US.
For a complete picture of Descartes-08’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
